Trial result ·
Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 (MINMON) Clinical Trial.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study looked at people with hepatitis C in a drug trial. The trial was called A5360, or MINMON. People took sofosbuvir/velpatasvir for 12 weeks, with few check-ups. The trial took place in several countries. The team used gene tests to find the virus type in each person. They also looked for virus changes that may weaken the drugs. Then they checked who was free of the virus after the drugs.
What they found
The trial had 399 people. The team could find the virus type in 389 of them. Full gene tests on the hard cases pointed to possible new forms of genotype 4. These are only provisional for now. They also found what may be a new form of genotype 7, called 7c. All people whose virus type was unclear at first got rid of the virus. This held even when some had virus changes tied to drug resistance. Fewer people got rid of the virus when they had genotype 3b. The authors link this to known virus changes that weaken this kind of drug. Overall, the drug pair cleared the virus at high rates across types.
What it means for patients
The authors say hepatitis C virus types vary a lot around the world. They say this drug pair worked well even for rare and new types. In their view, this backs simple plans like the one tested in MINMON. They see this as a step toward ending hepatitis C.
Why it is not certain yet
The abstract does not say how many people had each rare type. It does not give full numbers for each group. The new virus forms are only seen as possible new types so far. The genotype 3b result shows the drugs may work less well for some. This was one trial, so results may not hold everywhere.
Source
Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 (MINMON) Clinical Trial.
PubMed · PMID 42922282We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Hepatitis C publications